Bernardo Cortese
Latest contributions
CTO PCI: an evolving landscape
21 May 2026 – From EuroPCR 2026
Review the evolving landscape of chronic total occlusion (CTO) PCI with a focus on recent trends, contemporary management in multivessel disease, and innovative techniques such as retrograde approaches and titrated contrast recanalization. This session also addresses cost-effectiveness and drug-coated balloon (DCB) therapy outcomes from multicenter studies.
Hybrid percutaneous revascularisation: combining DES and DCB for optimal results
21 May 2026 – From EuroPCR 2026
This session delves into hybrid percutaneous revascularisation techniques that combine drug-eluting stents (DES) and drug-coated balloons (DCB) to achieve optimal clinical results. It highlights the clinical and anatomical scenarios suited for hybrid PCI, provides a step-by-step procedural approach, and discusses the potential benefits of integrating these...
MagicTouch sirolimus-coated balloon for coronary artery disease and peripheral artery disease treatment: where evidence meets experience
20 May 2026 – From EuroPCR 2026
This session examines the clinical evidence and experiential insights regarding the MagicTouch sirolimus-coated balloon (SCB) for treating coronary and peripheral artery disease. It reviews long-term comparative data versus paclitaxel-coated balloons, application techniques, integration into current practices, and findings from major trials such as SIRONA and SIMPLE-DM,...
DCB: does coating morphology matter for distal embolisation and clinical outcomes?
20 May 2026 – From EuroPCR 2026
Drug-coated balloon (DCB) therapy continues to evolve, with increasing attention on how coating design may influence drug transfer, vessel response and downstream clinical outcomes.
This EuroPCR 2026 session examines the role of coating morphology, comparing amorphous and crystalline technologies and their implications for drug delivery efficiency and...
New evidence for the use of DCB
20 May 2026 – From EuroPCR 2026
This session reviews emerging evidence supporting the use of drug-coated balloons (DCB) in complex PCI. It covers data from recent trials such as SELUTION De Novo, studies on vascular healing, restenosis patterns, long-term outcomes compared to DES, and optimal side branch treatment in bifurcation lesions.
Navigating the complexity of high bleeding risk
20 May 2026 – From EuroPCR 2026
Focusing on patients with high bleeding risk undergoing PCI, this session presents contemporary evidence on prevalence, procedural strategies with different stent types, antiplatelet therapy considerations including diabetic and sex-specific outcomes, and novel technologies such as sirolimus-coated balloons and machine learning models for restenosis prediction.
Is DCB a new valid option for coronary revascularisation?
22 May 2025 – From EuroPCR 2025
This session provides an in-depth evaluation of drug-coated balloons (DCB) as a valid option for coronary revascularisation. Topics include two-year follow-up comparisons between paclitaxel and sirolimus-coated balloons, clinical outcomes after bailout stenting post-DCB angioplasty, meta-analyses contrasting DCB and DES for large native coronary artery disease, and...
Which device for which patient: DES, BRS or DCB?
22 May 2025 – From EuroPCR 2025
This session provides comprehensive guidance on selecting the appropriate device—DES, BRS, or DCB—for individual patients and lesions. It examines patient and lesion characteristics, strengths and limitations of each device type, and regional considerations, illustrated by case presentations demonstrating practical device choice and resolution.
Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session delivers a comprehensive update on the MagicTouch sirolimus-coated balloon (SCB) and its expanding role in treating both coronary and peripheral artery disease (CAD/PAD). The session covers the extensive clinical trial program supporting MagicTouch as a versatile treatment option across multiple indications. It...
